BLADDER CANCER

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This phase II trial tests whether adding the immunotherapy drug durvalumab after surgery, chemotherapy, and radiation can help prevent bladder cancer from coming back in people with muscle-invasive bladder cancer. About 82 participants will receive either durvalumab or a placebo …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This phase 3 trial tests two new approaches for high-risk bladder cancer that hasn't spread into the muscle. One group gets a drug called TAR-200 placed directly into the bladder plus an immunotherapy drug (cetrelimab). Another group gets TAR-200 alone. These are compared to the …

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…

This study tests a pill called erdafitinib in 20 people whose non-muscle invasive bladder cancer has returned after standard treatments like BCG. All participants have a specific change in the FGFR3 gene, which the drug targets. They take the pill for about a month before their s…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response again…

This study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. …

This study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…

This early-phase study tested a new drug called UGN-201 in 10 people with bladder cancer who were scheduled to have their bladder removed. The main goal was to check the drug's safety and see if it caused any serious side effects or surgery delays. Researchers also looked for sig…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder surgery to prevent acute kidney injury. The surgery can reduce blood flow to the kidneys, and these drugs may help protect them. 90 adults with normal or mildly reduced kidney func…

This early-phase study tests a combination of two drugs—romidepsin and durvalumab—given directly into the bladder for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The goal is to see if the combination is safe and can shrink or eliminate tum…

This phase 2 trial is testing a drug called ado-trastuzumab emtansine (Kadcyla) in 131 adults with advanced solid tumors that have a specific HER2 gene change. The drug combines an antibody that targets HER2 with a chemotherapy agent, aiming to deliver treatment directly to cance…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) before bladder cancer surgery is safe and does not delay the operation. The goal is to shrink the tumor, making surgery more effective. It involves 52 adults with muscle-invasive bladder canc…

This phase 2 trial tests whether giving a live BCG vaccine directly into the bladder, followed by immunotherapy (atezolizumab) and standard chemotherapy (cisplatin/gemcitabine), can completely clear muscle-invasive bladder cancer before patients undergo bladder removal surgery. T…

This study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…

This study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) can prevent high-risk bladder cancer from coming back after surgery. About 230 adults with muscle-invasive bladder cancer will receive either the vaccine plus immunother…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and works better for people with advanced bladder cancer. About 54 participants will receive the combination treatment. The goal is to see if the combo…

This study tests whether the immunotherapy drug nivolumab, given after standard chemo-radiation, can help prevent bladder cancer from coming back. About 200 adults with localized muscle-invasive bladder cancer who cannot have bladder removal surgery are taking part. The main goal…

This Phase 2 trial tests whether adding visugromab to the immunotherapy nivolumab helps shrink muscle-invasive bladder cancer before surgery. The study includes 31 patients who cannot take or refuse standard cisplatin chemotherapy. The main goal is to see how many patients have n…

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study looks at how well a new robotic surgery system (Medtronic Hugo) works for urologic procedures like removing prostate, bladder, or kidney tumors. About 144 adults will have surgery with the robot, and doctors will check if the surgery is completed without switching to a…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to…

This study tests a drug called abemaciclib in 20 people with bladder cancer who cannot receive standard chemotherapy. Participants take the drug before their scheduled surgery to remove the bladder. Researchers will compare tumor samples taken before and after treatment to see ho…

This study tested a combination of two chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder for people with early-stage bladder cancer who had not received standard BCG therapy. The goal was to see if this treatment could prevent the cancer from coming …

This study tests whether combining two immune-boosting drugs, pembrolizumab and BCG, can keep high-risk bladder cancer from coming back. About 45 people with early-stage but aggressive bladder cancer will receive this combination as their first treatment. The goal is to see if mo…

This study tests a new treatment for people with a type of bladder cancer that has not improved with standard therapy. The treatment combines a standard immunotherapy (BCG) with an experimental drug (N-803), both given directly into the bladder through a catheter. The goal is to …

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people whose metastatic cancer has started to progress. About 69 adults with melanoma, lung, bladder, kidney, or head/neck cancers will receive radiation to up…

This phase 2 trial tested a combination of four chemotherapy drugs (5-FU, leucovorin, gemcitabine, and cisplatin) in 46 people with advanced or inoperable adenocarcinoma of the bladder, urethra, or urachus. The goal was to see how many patients' tumors shrank or disappeared. Rese…

This study compares two imaging techniques—CT urography (CTU) and intravenous urography (IVU)—in 133 bladder cancer patients to see if CTU alone can effectively monitor the disease. Researchers want to determine if CTU provides clear enough images of the urinary tract to replace …

This study is testing a new urine test that looks for specific markers of bladder cancer. The goal is to see if this simple, non-invasive test can accurately detect bladder cancer in 450 people who have blood in their urine, potentially reducing the need for a more invasive camer…

This study is testing a new urine test to detect bladder cancer early in people at high risk, such as smokers over 50. Researchers will check how accurate the test is and use the data to build a risk calculator. The goal is to offer a non-invasive way to catch the disease sooner.

This study is testing a new urine test called Bladder CARE™ to see if it can detect bladder cancer in people whose standard tests (cystoscopy or cytology) gave unclear results. About 80 adults with suspicious but inconclusive findings will provide a urine sample before their rout…

This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see …

This study tests whether whole brain radiation can lower the chance of brain tumors in people with small cell carcinoma of the urinary tract (including the bladder). The 31 participants have already had chemotherapy and responded well. They receive radiation to the brain for 3 we…

This study tested a program to help bladder cancer patients recover better after bladder removal surgery. The program included extra monitoring and support before, during, and after the operation to catch problems early. The goal was to reduce complications within 90 days after s…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…

This study tests whether JING SI HERBAL TEA, a dietary supplement with herbal extracts, can ease lower urinary tract symptoms in bladder cancer patients who have received intravesical therapy. One hundred participants will receive either the herbal tea or a placebo, and their uri…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study follows 550 people with bladder cancer to understand how treatments like surgery affect their quality of life. Researchers want to learn what patients go through so doctors can offer better support and clearer information. The goal is to improve care, not to test a new…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. Researchers will ask 120 people who had surgery in the last year to fill out questionnaires about their medical costs, travel expenses, and support needs. The goal is to un…

This study compares two common treatments for recurrent non-muscle-invasive bladder cancer: medical therapy (drugs placed in the bladder) and surgery (bladder removal). Researchers will track quality of life and patient experiences in 570 adults to see which approach works better…

This study follows 204 people with bladder cancer to see how their quality of life changes after treatment like surgery or radiation. Participants fill out surveys about physical function, pain, fatigue, anxiety, and bladder, bowel, and sexual health. The goal is to understand ho…

This study follows 600 people with non-muscle invasive bladder cancer to see how changes in smoking habits and body weight after diagnosis affect the chance of cancer coming back. Participants fill out questionnaires and provide saliva or urine samples over time. The goal is to l…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study looks at how bladder cancer treatments affect people's quality of life years later. Researchers will ask 2000 patients in Denmark about their long-term side effects and what factors might make these worse. The goal is to better understand the real-life impact of treatm…

This study looks at how a person's genes and lifestyle choices, like smoking, affect their risk of getting bladder cancer. Researchers will compare over 6,000 people with and without bladder cancer to find patterns. The goal is to better understand who is most at risk, which coul…

This study analyzes genetic changes in bladder cancer cells from 5,000 participants. Researchers hope to identify key chromosomal events linked to the disease. No treatment is given; the goal is to gather knowledge that may inform future research.

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) alone or with entinostat affects immune markers in people with muscle-invasive bladder cancer who cannot or choose not to have standard chemotherapy. Twenty participants receive the drugs before the…

This study looks at whether wearable fitness trackers like the Fitbit Sense 2 can help doctors spot early signs of complications in patients recovering from bladder removal surgery. Fifty participants will wear the device and answer daily surveys for up to two weeks before surger…

This study follows 200 bladder cancer patients who have had their bladder removed (cystectomy) to understand their information needs and how rehabilitation support can be improved. Researchers will track patients over time to see what help they need and how well they cope. The go…

This pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …

This study creates a large registry of people with and without urothelial cancer (bladder, ureter, or renal pelvis cancer) to learn how genes and lifestyle affect risk. Participants provide a saliva sample and fill out questionnaires. The goal is to improve prevention, diagnosis,…